Data across VALOR-HCM, EXPLORER-HCM, AUGUSTUS and other studies continue to demonstrate the safety and efficacy of the company’s cardiovascular portfolio
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research demonstrating the strength of the company’s cardiovascular franchise at the American Heart Association’s (AHA) annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022. Findings from clinical, patient-reported outcomes and real-world studies will be presented across the cardiovascular portfolio. Notably, one abstract from the CAMZYOS® (mavacamten) development program was accepted as a featured science presentation demonstrating advancements in the treatment of obstructive hypertrophic cardiomyopathy (HCM).
“The AHA annual Scientific Sessions is an important congress for us to share new data that is adding to the growing body of evidence demonstrating the continued positive, long-term impact our treatments are having for cardiovascular patients globally,” said Roland Chen, MD, senior vice president and head of cardiovascular development, Global Drug Development at Bristol Myers Squibb. “We continue to pursue the development of innovative, safe, effective and durable treatment options that improve patients’ lives, and are proud to showcase further analysis from our programs in obstructive hypertrophic cardiomyopathy and thrombosis.”
Key presentations include:
Summary of Presentations
Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at the AHA Annual Scientific Sessions 2022 include:
Abstract Title | Primary Author | Type/# | Session Title | Time (CT) |
Saturday, November 5, 2022 | ||||
Mavacamten Treatment in Patients with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Pooled Safety Analysis of 5 Clinical Trials
| Fermin, D | Poster - SA2183
| HF.APS.P33 - Novel Drugs and Strategies for Heart Failure With Preserved Ejection Fraction | 3:00 PM - 4:00 PM |
Impact of Mavacamten on Artificial Intelligence Electrocardiographic Diagnosis of Hypertrophic Cardiomyopathy in the EXPLORER-HCM Trial | Siontis, K | Poster - SA2182 | HF.APS.P33 - Novel Drugs and Strategies for Heart Failure With Preserved Ejection Fraction | 3:00 PM - 4:00 PM |
Sunday, November 6, 2022 | ||||
Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Active Blinded Crossover Results From VALOR-HCM Trial | Desai, M | FS.02 -New Insights - Cardiac Surgery | 9:30 AM - 9:42 AM | |
The Association of Echocardiographic Parameters with Health Status in Patients with Obstructive Hypertrophic Cardiomyopathy. Insights from the EXPLORER-HCM Trial | Arnold, S | Oral - | QU.AOS.465 - Improving Cardiovascular Health Outcomes Through Real-World Science | 10:06 AM - 10:16 AM |
Effect of Mavacamten on Systolic Anterior Motion of the Mitral Valve and Mitral Regurgitation in Patients with Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM Study | Cremer, P | Moderated Poster - MP129 | HF.MDP19 - New Insights From Clinical Trials: Pharmacologic Therapy for Heart Failure | 10:30 AM - 10:35 AM |
Predictors of Primary Non-Adherence in Patients With Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the US* | Hines, DM | Poster - MP111 | QU.MDP32 - Improving Cardiovascular Health: Prediction, Processes and Programs | 12:00 PM - 12:05 PM |
Effect of Mavacamten on Diastolic Function in Patients with Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM Study | Cremer, P | Oral - | IM.AOS.373 - Charles T. Dotter Memorial Lecture | 4:18 PM - 4:28 PM |
Monday, November 7, 2022 | ||||
Racial Disparities and Geographic Variation in Anticoagulant Treatment Among Medicare Beneficiaries With Non-Valvular Atrial Fibrillation in the United States* | Kang, A | Oral - | EP.RFO32 - Out of Rhythm and Out of Step: Prevention and Management of Atrial Fibrillation | 11:50 AM - 11:55 AM |
Association Between Oral Anticoagulant Type and Hospital Readmission Rates Following Myocardial Infarction With Percutaneous Coronary Intervention in Patients With Nonvalvular Atrial Fibrillation* | Desai, N | Poster - MO4086 | EA.APS.P278 - Broadening Our Understanding of Anticoagulation in the Setting of Atrial Fibrillation
| 1:45 PM - 2:45 PM |
Benefits of Apixaban Over Warfarin are Preserved Independent of Warfarin Time in Therapeutic Range: Insights From the AUGUSTUS Trial* | Harrington, J | Poster - | EA.APS.P278 - Broadening Our Understanding of Anticoagulation in the Setting of Atrial Fibrillation | 1:45 PM - 2:45 PM |
Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial* | Fudim, M | Poster - MO4087 | EA.APS.P278 - Broadening Our Understanding of Anticoagulation in the Setting of Atrial Fibrillation | 1:45 PM - 2:45 PM |
*Sponsored by the Bristol Myers Squibb-Pfizer Alliance
About CAMZYOS (mavacamten)
CAMZYOS (mavacamten) is the first and only cardiac myosin inhibitor approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic LVOT obstruction and improves cardiac filling pressures.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HEART FAILURE
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF